id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3532-0002,FDA,FDA-2024-E-3532,"Patent Extension Application from Morgan, Lewis & Bockius LLP (on behalf of lovance Biotherapeutics, Inc. (""lovance""))",Other,Application,2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:33:31Z,,0,0,090000648660a4b9
FDA-2024-E-3532-0001,FDA,FDA-2024-E-3532,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:32:16Z,,0,0,090000648660a4b8